CRSP241004C47000
- 0.43
- -0.57-57.00%
CRISPR Therapeutics Newsroom
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Express News | Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Have Endured a 59% Loss From Investing in the Stock Three Years Ago
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Express News | CRISPR Therapeutics AG : Truist Securities Cuts Target Price to $100 From $120
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Express News | Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
Crispr Therapeutics Is Maintained at Hold by Stifel